Salvatore Albani MD, PhD

Salvatore Albani is an internationally renowned rheumatologist and immunologist. He is a Professor at Duke-NUS Medical School and Director of the Translational Immunology Institute at SingHealth- Duke-NUS Medical Centre. Before joining Duke-NUS, Professor Albani served as director of the Translational Medicine Unit at the Clinical Investigation Institute at the University of California, San Diego, where he also was a professor of Medicine and Pediatrics. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He has developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from the idea to the conclusion of Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals.

Salvatore Albani has been responsible for the conception and execution of each of the stages of this complex itinerary, which spans a wide and diverse gradient of technologies and challenges. These include molecular immunology, lead identification and validation, intellectual property, CMC (Chemistry, Manufacturing, and Controls), IND (Investigational New Drug filings), trial design, data management and analysis, and interfacing with Venture Capital and Pharma, leading complex groups in a multi-center setting, etc. The technology platform has applications in diseases that could benefit from a restoration of immune tolerance. This translational research itinerary has been the original backbone of his career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc, H factor 34) and by approximately 100 patents. The development of high throughput technology platforms is also part of his scientific career. These platforms aim to provide tools for knowledge-based diagnostic and therapeutic decisions.